Profound Medical Corp. (PROF)
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
Profound Medical Corp.
Trials need funding. See this company's dilution risk and cash position.
- Not applicableCompleted
Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer
MR-Guided Transurethral US Ablation of Prostate Tissue
Prostate Cancer
NCT01686958Enrollment30StartMar 2013Primary CompletionMar 2015CompletionJun 2019 - Not applicableActive, not recruiting
Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer
MRI-guided Transurethral Ultrasound Ablation
Prostate Cancer
NCT02766543Enrollment150StartSep 2016Primary CompletionFeb 2019CompletionSep 2028est. - ObservationalRecruiting
Customized TULSA-PRO Ablation Registry
TULSA Procedure
Prostate Cancer, Prostate Adenocarcinoma +1
NCT05001477Enrollment1,000StartOct 2021Primary CompletionOct 2026est.CompletionOct 2061est. - Not applicableActive, not recruiting
A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer
Radical Prostatectomy, TULSA Procedure
Prostate Cancer, Prostate Adenocarcinoma
NCT05027477Enrollment201StartNov 2021Primary CompletionAug 2026est.CompletionAug 2036est.
| Drug / Therapy | Link | ||
|---|---|---|---|
| Not applicable | Completed | MR-Guided Transurethral US Ablation of Prostate Tissue | NCT01686958 |
| Not applicable | Active, not recruiting | MRI-guided Transurethral Ultrasound Ablation | NCT02766543 |
| Observational | Recruiting | TULSA Procedure | NCT05001477 |
| Not applicable | Active, not recruiting | Radical Prostatectomy, TULSA Procedure | NCT05027477 |